Buspirone: Independent Evidence on Anxiety (GAD), Side Effects & Interactions
Buspirone (BuSpar): what independent reviews show for generalised anxiety, why it is slow and non-sedating, CYP3A4 interactions, safety and who funds the evidence.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Buspirone (BuSpar): what independent reviews show for generalised anxiety, why it is slow and non-sedating, CYP3A4 interactions, safety and who funds the evidence.
Lorazepam (Ativan) is strongly evidenced for stopping status epilepticus but limited to 2–4 weeks for anxiety. Independent evidence on risks, withdrawal and funding.
Alprazolam (Xanax) eases panic and anxiety fast, but guidelines limit it to crises. Independent evidence on benefits, dependence, withdrawal, misuse and who funds it.
Independent review of nortriptyline: depression and late-life relapse evidence, off-label smoking cessation, weak nerve-pain data, overdose risk and blood levels.
Independent review of agomelatine (Valdoxan): small benefit over placebo, good tolerability, unpublished trials, liver-test rules and who funded the evidence.
Vortioxetine (Brintellix/Trintellix) beats placebo modestly but is not proven better than older antidepressants; its cognitive claims rest on maker-funded trials.
Venlafaxine (Effexor) works for depression and anxiety, but independent evidence flags blood pressure rises, hard withdrawal and higher overdose toxicity.
Trazodone is licensed for depression but mostly prescribed off-label for sleep. Independent evidence on benefits, falls, priapism, withdrawal and funding.
Pregabalin (Lyrica) helps a minority with nerve pain, focal epilepsy or GAD, but misuse, dependence and breathing risks with opioids made it a UK controlled drug.
Paroxetine (Seroxat/Paxil) helps adult depression and anxiety short term, but has hard withdrawal, pregnancy and tamoxifen warnings, and the Study 329 history.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.